“Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study”. Clinical Pharmacology in Drug Development6 (5): 439–447. (September 2017). doi:10.1002/cpdd.364. PMID28783873.
“Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study”. Clinical Pharmacology in Drug Development6 (5): 439–447. (September 2017). doi:10.1002/cpdd.364. PMID28783873.